Related Experiment Video

Updated: Jul 19, 2026

Analytical Techniques for Assaying Nitric Oxide Bioactivity
11:28

Analytical Techniques for Assaying Nitric Oxide Bioactivity

Published on: June 18, 2012

Nitric oxide-releasing aspirin: will it say NO to atherothrombosis?

Charalambos Antoniades, Dimitris Tousoulis, Christodoulos Stefanadis

    International Journal of Cardiology
    |September 26, 2006
    PubMed

    Insights

    Nitric oxide-releasing aspirin offers a promising alternative to traditional aspirin for cardiovascular disease, potentially reducing gastrointestinal side effects while maintaining antithrombotic benefits. Further clinical trials are needed to confirm its efficacy and safety.

    Area of Science:

    • Cardiovascular Medicine
    • Pharmacology

    Background:

    • Aspirin is a key anti-platelet agent for coronary atherosclerosis but causes gastrointestinal toxicity.
    • Nitric oxide-releasing aspirin (NO-aspirin) presents a novel therapeutic approach.

    Discussion:

    • NO-aspirin dissociates into aspirin and nitric oxide (NO), providing antithrombotic and gastroprotective effects.
    • It enhances vascular NO bioavailability, potentially offering antiatherogenic properties.
    • Emerging data suggest benefits for vein graft patency in coronary artery bypass grafting (CABG).

    Key Insights:

    • NO-aspirin combines aspirin's antithrombotic action with NO's gastroprotective and vascular benefits.
    • This dual action may mitigate aspirin's common gastrointestinal side effects.
    • Potential improvements in vein graft function post-CABG are being investigated.

    Outlook:

    • Ongoing large-scale clinical trials are crucial to validate the role of NO-aspirin in cardiovascular disease management.
    • Further research will determine the long-term efficacy and safety profile of NO-aspirin.
    • NO-aspirin could represent a significant advancement in managing patients with atherosclerosis and high thrombotic risk.

    More Related Videos

    En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries08:58

    En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

    Published on: February 25, 2016

    Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds08:23

    Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds

    Published on: February 16, 2022

    Related Concept Videos

    Nitric Oxide Signaling Pathway01:28

    Nitric Oxide Signaling Pathway

    Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
    Antianginal Drugs: Nitrates and β-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    Antihypertensive Drugs: Vasodilators01:23

    Antihypertensive Drugs: Vasodilators

    Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Angina IV: Management01:26

    Angina IV: Management

    IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...